SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Pierre Le Moyne d'Iberville — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientPierre Le Moyne d'Iberville
Date of birth1661-07-16
IdentifiersMRN HR-ET014-SYN-TD; SSN (made up) 000-14-7260
Document date1705-03-31
AuthorMarguerite Delacroix-Boateng, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-week review after chloroquine and primaquine. [S]

History of Present Illness

Mr. Le Moyne d'Iberville returns four weeks after starting treatment. He took all four doses of chloroquine, with mild nausea on the first day, and finished the 14 days of primaquine two weeks ago, taking it with food; he had mild stomach cramps for a few days and no dark urine, breathlessness or blue lips. He has had no fever. He did not have the smear and PCR that were meant for a week after the last primaquine dose, because the date was not booked. He explained the fever plan back correctly. [S]

ElementDetail
ChloroquineAll doses taken; mild nausea on the first day
Primaquine14 days completed two weeks ago; mild stomach cramps
FeverNone
Missed testPost-treatment smear and PCR not done

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or chills; energy better
GastrointestinalNegativeCramps settled; no jaundice
GenitourinaryNegativeNo dark urine

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total)Oral route1705-03-03 to 1705-03-05completedS
Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days30 mg base once daily for 14 daysOral route1705-03-03 to 1705-03-16completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1705-03-31Body height175cmS
1705-03-31Body weight69kgS
1705-03-31Body mass index (BMI) [Ratio]22.5kg/m2S
1705-03-31Systolic blood pressure122mm[Hg]S
1705-03-31Diastolic blood pressure78mm[Hg]S
1705-03-31Heart rate66/minS
1705-03-31Respiratory rate14/minS
1705-03-31Body temperature36.6CelS
1705-03-31Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1705-03-31Hemoglobin [Mass/volume] in Blood13.6g/dL13.2-17.1 g/dLNormalS
1705-03-31Platelets [#/volume] in Blood by Automated count21210*3/uL150-400 10*3/uLNormalS
1705-03-31Bilirubin.total [Mass/volume] in Serum or Plasma0.7mg/dL0.3-1.2 mg/dLNormalS

Physical Exam

Vital signs recorded on 1705-03-31; see the Vital Signs section. [S]

SystemFinding
GeneralWell; temperature 36.6 C, blood pressure 122/78, pulse 66, weight 69.0 kg
EyesNo pallor; sclerae white
SkinNo cyanosis

Problems

ProblemClinical statusVerificationCodeProvenance
Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requestedresolvedconfirmed R50.9S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation.
Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PDresolvedconfirmed B51.9S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic.
Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccinesactiveconfirmed Z71.84S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count and bilirubin for hemolysis on primaquineBaseline, then after the courseCompleted todayHemoglobin 13.6 g/dL, platelets 212 x10^3/uL, bilirubin 0.7 mg/dL: no hemolysis
LaboratoryFollow-up blood smear after treatment (ideally within one week of finishing)About one week after finishingCompleted todaySmear negative today; PCR sent. Protocol deviation: the smear and PCR ordered for one week after the last primaquine dose were not drawn, because no date was booked; they were drawn today, two weeks after finishing. No harm resulted: the smear is negative and he has had no fever. Corrective action: book post-treatment tests with a date when treatment starts
Medication safetyAdverse effects: nausea, abdominal pain, dark urine, breathlessness, cyanosisDuring the courseCompleted todayMild nausea on chloroquine and mild cramps on primaquine; no dark urine or cyanosis
Medication safetyAdherence to the full courseAt the end of the courseCompleted todayAll doses of both medicines taken
Self-managementRelapse surveillance and the fever action planEvery visitCompleted todayNo fever; explained the plan back correctly

Goal progress:

Guideline basis: Treatment of Uncomplicated Malaria (clinical guidance) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026)

Follow-up: Preventive visit in three weeks. Pre-travel visit in the summer. Next scheduled visit 1705-04-21: periodic adult preventive visit. [S]